Poster Subject Index
γ’ fibrinogen, 169
A4V mutation, 105, 186
AAV, 220
AAV9, 227
abstractive skills, 310
ACP, 385
ADAR2 cKO mice, 233
adipose derived stem cells, 226
adult SMA, 246
advance care planning, 385
advance directive, 388
advanced methods, 252
adverse events, 358
African, 110
age, 183
ageing, 171
aggregation pathway, 120
agraphia, 312
aid, 365
aids and adaptations, 367
airway protection, 332
algal blooms, 117
ALS mutations, 174
ALS patients, 378
ALS treatment strategy, 217
ALS-frontotemporal spectrum disorder, 309, 314
ALSFRS-R, 192, 267, 268, 295, 298, 363
ALS-FTD, 299, 300
alternative and augmentative communication, 379
Alzheimer's disease, 299, 305
AMP-activated kinase, 141
amyotrophic lateral sclerosis, 122
animal model, 147, 170
antioxidants, 112
antisense-oligonucleotide, 112, 237
antibiotics, 183
antibody, 237
anti-inflammatory therapy, 225
ANXA11, 106, 107, 149
anxiety, 376
artificial nutrition, 351
aspiration, 340
assessment, 180, 344
assistive technology devices, 366
assistive technology, 367
association study, 92
astrocytes, 131, 156, 167
atomic force microscopy, 169
attitudes, 319
ATXN2, 110, 282
audit, 304
autoantibodies, 212
autophagy, 112, 113, 139, 141, 159, 168, 230
autoregulation, 126
awareness, 319
axon growth, 97
axon, 164
axonal transport, 116, 121
barriers to treatment, 361
behavior and motor coordination tests, 225
behavioral impairment, 302
behavioral tests, 218
behaviour, 139, 306, 309, 315, 321
Betz cells, 174
big data, 189, 191
bioelectrical impedance analysis, 346
bioinformatics, 91
biological samples, 94
biomarker, 198, 199, 202, 203, 205, 208, 211, 212, 214, 215, 242, 245, 250, 256, 259, 260, 284
biotelemetry, 268
blood brain barrier, 148, 200
blood, 205, 207
BMAA, 116, 153, 180
body composition, 346
bornavirus, 221
botulinum toxin, 344
brain cortex, 171
brain MRI, 261
brain network, 258
BSCB, 137
bulbar assessment, 377
bulbar dysfunction, 337, 340
bulbar function, 297, 339, 341, 342
bulbar onset, 284, 290
bulbar, 109, 245, 330, 344
burden of disease, 195
C9, 165
C9ORF72 expansion, 100
C9ORF72, 92, 93, 101, 102, 110, 118, 156, 157, 161, 162, 163, 164, 166, 168, 173, 185, 186, 220, 237, 282, 300, 313
CADASIL, 292
cannabinoid, 133, 233, 234
care, 310, 373
caregiver burden, 318
caregiver, 373, 374
carer burden, 309
carer, 322
case management, 375
case-cohort, 187
case-control, 183
catalyzed assembly, 172
causes of death, 196
CB2 receptor, 133
C-bouton, 142
CCNF gene, 104
CD8+ T cells, 143
cell therapy, 226
cell-free DNA, 207
cell-to-cell propagation, 152
CHAB, 180
chaperone-mediated autophagy, 228
characterisation, 138
chest x-rays, 329
children, 323
Chinese cohort, 103
Chinese population, 104, 105, 106
chirality, 153
chitotriosidase, 201
cholesterol, 203
chromatin remodelling, 124
cilia, 107
client-centred, 370
clinical care, 293, 322, 360, 363, 368
clinical characteristics, 289
clinical decission support, 357
clinical feature, 276
clinical genetics, 101
clinical phenotype, 283
clinical staging, 273
clinical trial design, 264
clinical trial, 213, 268, 272, 275, 277, 332
clinical trials, 296
clinician-patient communication, 386
clinico–pathological correlations, 299
cluster, 180
CO2, 334
cognition, 176, 253, 301, 306, 313, 315
Cognitive assessment, 302
cognitive endophenotype, 321
cognitive impairment, 261, 302, 304
cognitive test, 311
cognitive, 303, 304
cognitive/behavioural impairment, 306
coherence, 240
collaboration, 191, 370
communication ability stage, 339
communication barriers, 378
community team, 370
co-morbidities, 194
confocal endomicroscopy, 248
connectivity, 141, 247, 255
contaminant, 179
contractility, 141
coping, 316
copper, 215, 235
cortical thickness, 253, 254
cough assist, 337
cough, 339
cramps, 278
c-reactive protein, 202
creatine kinase, 209, 210, 285
CSF, 202, 212
CSMN, 224
CST hyperintensity, 258
CuATSM, 235, 280
cutaneous silent period, 244
cut-off values, 307
cyanobacteria, 153, 182
cystatin c, 141
cytotoxicity, 120
data harmonisation, 94
database, 178, 205
data-driven, 98
ddPCR, 206
decision making, 311, 350, 383
decision-making swallowing, 347
dementia, 312, 315
demographic factors, 387
dental restoration, 182
depression, 194, 311, 315
development plan, 272
diagnosis, 291, 293, 341, 353
diagnostic delay, 293, 294
diagnostic pathway, 294
diagnostic yield, 99
diaphragm, 328, 329
digital phenotyping, 296
digital platform, 375
Dimensional Apathy Scale, 308
dipeptide repeats, 152, 164
direct conversion, 176
disability, 193, 311
disaster, 383
disease model, 154
disease modifier, 91
disease modifying, 280
disease prediction, 298
disease progression, 191, 200, 257, 286, 297, 345
Distress, 310
DNA damage, 124
DNA methylation, 96
dog-assisted therapy, 376
dosing, 272
DPRs, 166
DREADDs, 137
Drosophila, 146, 151, 152
drug delivery, 229
drug development, 219, 236
drug safety benchmarks, 361
drug testing, 231
drug, 360
drug-drug interaction, 358
DTI, 254
dynamometry, 355
dysarthria, 378
dysphagia, 271, 332, 339, 344
dystussia, 332
early diagnosis, 189
early hyperexcitability, 122
early palliative care, 385
early pathological mechanisms, 144
early stage, 256
ECAS, 98, 303, 304, 305, 306, 307
edaravone, 272, 274, 358, 359, 360, 362, 363
education, 293
EEG, 240, 247
e-health, 356
electric impedance myography, 244
electromyography, 244, 247
electroneuromyography, 242
electronic record keeping, 354
electronic, 368
electrophysiology, 277
elemental signature, 215
EMG, 240, 242
empathy, 320
end of life care, 335, 387
end-of-life decisions, 319
endophenotype, 282
energy metabolism, 150, 154
enrichment, 264
environment, 179, 180, 182
environmental risk factors, 117, 184, 185
epidemiology, 178, 181, 187, 188, 189, 197, 198
epigenetics, 96, 163
ER-Golgi pathology, 129
erythrocyte, 204
erythropoietin, 276
European populations, 293
excessive daytime sleepiness, 382
excitability, 157
exosomes, 159, 160, 161, 206, 223, 224
experiences, 373
exposure, 182
extracellular vescicles, 209
extrinsic factors, 151
eye tracking system, 310
factor analysis, 297
family aggregation, 282
family history, 93
family relations, 378
family, 321
fasciculation potential, 241
fasciculation, 242
fatigue, 244, 342
fatty acid metabolism, 217
fatty acid, 204
ferroptosis, 235, 236
fibroblast, 157
fish consumption, 182
FLAIR, 259
forced vital capacity, 327, 348
FORTITUDE-ALS, 266, 279
FOSMN, 292
founder effect, 186
fractional amplitude of low-frequency fluctuations, 249
FRET/BRET, 125
frontotemporal degeneration, 252
frontotemporal dementia, 252, 298, 305, 313
Frontotemporal syndrome, 302
functional connectivity, 256
functional scales, 271
functionality, 295
FUS, 111, 129, 139, 161, 231, 240
gastrostomy, 347, 349, 350, 351
GDNF, 131
gene therapy, 223, 227
gene–environment interaction, 185
genetic heterogeneity, 282
genetic modifier, 137
genetic panel, 98
genetic testing, 93, 101
genetics, 98, 109, 283, 298
genomics, 94
genotype, 243
geographical variation, 369
geospatial, 179
glia, 198
glutamine, 110
glycogen, 131
glycosphingolipids, 203
Golgi apparatus, 135
graph theory, 258
gut microbiome, 200
heat shock proteins, 123
high-throughput screening, 125
high-throughput, 150
histology, 199
home care, 383
home-cared patients, 338
hope, 317
hospice, 304, 335
HSP, 257
human iPSC-derived motor neurons, 154, 232
human, 259
hydroxybutyrate dehydrogenase, 209
hypermethylation, 96
hypothalamus, 254
iCLIP, 126
IDR, 126
Ighmbp2, 137
IL-17A, 148
imaging, 260
immunotherapy, 237
impaired saccades, 240
impedance spectroscopy, 245
incidence, 178
independent component analysis, 256
individualized medicine, 357
inflammation, 196, 200, 262
inflammatory cytokines, 171
informal caregivers, 320
information gathering, 386
information-source, 373
infusion, 226
inosine, 118
insula, 251
intermediate filaments, 115
Interleukin (IL)-6, 325
international conference, 291
international, 315
intervention, 385
intraspinal transplantation, 276
intrathecal transplantation, 276
intravenous drug administration, 361
invasive ventilation, 196
in vivo, 219, 223
in vitro, 112
IP3 receptor, 155
iPS models, 156, 157, 163
iPSC bank, 154
iPSC, 154, 155, 161, 164, 165, 166, 167, 224
iPSC-derived motor neuron, 162
iron, 226
island, 374
judgment, 311
juvenile, 111, 288
KATP channel, 95
KIF5A, 105
kinesin family member 5A, 104
knowledge, 319
Korean, 108
L84FSOD1 cell model, 119
lactate dehydrogenase, 209
laminins, 114
language, 313
laryngeal electromyography, 245
L-BMAA, 159
LD score regression, 92
left upper limb onset, 295
leukocytes, 201
levosimendan, 280
LIC TRAINER, 326
Likert scale, 371
lipidomics, 203
liraglutide, 219
lncRNA, 96
longitudinal, 252, 314
lower extremity strength, 268
lower limb onset, 285
lower motor neurons, 144
L-serine, 159
LST, 259
lung capacity, 330
lung insufflation capacity, 326
lung pathology, 335
LVPN, 120
lysosomes, 203
machine learning, 191
management, 337
mapping, 180
Markov model, 273
masitinib, 230
mass spectrometry imaging, 215
mass spectrometry, 173
mast cells, 230
matrin-3, 118
Mctp1, 175
mechanical insufflation-exsufflation, 336, 337
mechanical ventilation, 337
medical decision-making, 386
medical ethics, 353
mendelian randomization, 184
mental disability, 111
mercury, 182
mesechymal stem cell, 275
metabolism, 118
metabolism, 166, 283
metagenomic, 200
methylation profiling, 207
microglia, 127
microbiota, 217
microglia, 95, 202
microparticles, 160
microRNA, 115, 124, 174, 206, 208
miR-338-3p, 131
miRNA, 175, 227
misfolded SOD1, 228
mitochondria, 121, 164, 166, 168, 221
mitochondrial DNA, 207
mitochondriomics, 188
mitophagy, 168
MMT, 190
mOBFRS, 271
mobile app, 297
mobility, 368
mode of disease progression, 284
modifiers, 170
Mongolia, 102
monitoring, 297
monounsaturated fatty acids, 146
morpholino, 165
mortality, 197, 351
motoneurons, 222
motor cortex, 207
motor neuron, 127, 128, 150, 157, 161
motor unit, 141
mouse model, 121, 132, 135, 137, 139, 140, 142, 144, 145, 219, 221, 226, 231, 232
MRI, 199, 250, 251, 252, 254, 256, 257, 259
MRI/PET, 229
mTOR, 230
multicenter, 250
multidisciplinary approach, 348
multidisciplinary care, 355, 356
multidisciplinary models, 372
multi-electrode array, 122
multiple sclerosis, 196
MUNIX, 246
muscarinic receptors, 221
muscle cells, 114
muscle ultrasonography, 241
muscle, 159, 161, 215, 280
mutation, 100, 104
myasthenia gravis, 341
nanoparticles, 229
nasofibroscopy, 245
national, 265
native conformation stabilization, 217
NEALS, 264
necroptosis, 142
needle electromyography, 241
NEK1, 107
NEMF, 130, 132
neuronal hyperexcitability, 121
neuregulin, 142
neuromuscular junction, 114
neurotoxicity, 116
neurotoxins, 117
NeuroBANK, 191
neurochondrin, 114
neurodegeneration, 132, 349
neurodegenerative, 98
neurofilament light, 212
neurofilament, 211, 212, 213
neurogenesis, 97
neurogenic niche activity, 237
neuroimaging, 255
neuroinflammation, 95, 143, 198, 201, 228
neuromuscular junction, 133, 139, 140, 221, 233, 248
neuron, 118
neuropathic pain, 194
neuropathology, 174
neuroprotection, 133, 136, 159, 232
neuropsychology, 303, 310, 313, 314, 321
neurotoxic proteins, 206
neutrophils, 230
neutrophil-to-lymphocyte ratio, 286
new formulation, 272
NGS, 91, 99, 107
NHEJ, 124
NICE guidelines, 301
NIV, 247, 266, 328, 331, 332, 334, 335, 351
noninvasive respiratory aids, 336
non-LTR retrotransposons, 94
non-viral, 223
NOTCH3, 292
novel mutation, 104, 106
NPPV, 384
NSC-34, 113
nuclear pore, 130
nucleocytoplasmic transport, 130, 158
nurse, 384
nusinersen, 206
nutrition, 347
nutritional status, 346
obstructive sleep apnea, 328
online support, 320
onset, 96, 183
opioid, 384
optogenetic control of muscle function, 130
oral secretions, 344, 345
orthosis, 365
outcome measure, 268, 271, 296, 355
oxidative stress, 116, 128, 136, 198, 236, 364
oxidoreductase, 274
pain, 278
palliative care, 319, 380, 381
paravertebral block, 349
passage reading, 377
pathogenesis, 103
patient autonomy, 353
patient heterogeneity, 172
patient preference, 195
patient reported outcomes, 360, 366, 376
patient stratification, 172, 190
patient support, 363
patient-centred care, 356
patient-reported outcome, 297
PBMCs, 168
PEG, 347, 348, 351
peripheral blood cells, 119
percutaneous endoscopic gastrostomy, 348
peripheral nerve graft, 130
perisynaptic Schwann cells, 221
phase 1, 280
phenotype, 187, 290, 292
phenotyping, 287
physical activity, 185
physical function, 383
physician assisted death, 318
physician experience, 363
physicians, 387
physiotherapy, 376
plasma, 209
platform, 368
pleiotropy, 321
PLS, 291
pneumonia, 187
pneumothorax, 337
PNS, 262
politherapy, 358
polyneuropathy, 243
polyunsaturated fatty acids, 146
population register, 178
postmarketing safety, 359
post-mortem, 335
potassium channel, 176
PPD, 385
precision medicine, 112
preclinical models, 239
pre-clinical, 234
prediction, 190, 296
preparation, 383
prescribing practices, 266
pressure injury, 366
prevalence, 328
primary lateral sclerosis, 290
prion mechanism, 129
protein aggregation, 123
protein homeostasis pathways, 119
protein homeostasis, 123
PRO, 271
probiotics, 217
procedural outcome, 349
professional standards, 353
prognosis, 191, 202, 358
prognostic biomarker, 213
progression rates, 357
progression, 192, 251, 298
progressive chronic neurological diseases, 385
propagation, 146
protein aggregation, 224
protein homeostasis, 135
protein knockdown, 228
protein misfolding, 146, 213
protein, 174
proteomics, 140
proteostasis, 172
PSAM/PSEM, 137
pseudobulbar affect, 341
psychiatric, 321
psychology, 322
Psychological, 310
psychometric properties, 302
psychosocial, 323
PXT864, 232
PYGB, 131
qualitative research, 380
qualitative, 316, 317
quality care, 371
quality improvement, 368
quality of life, 194, 315, 316, 323, 371
quality, 287
raman spectroscopy, 215
rare variant, 91
Rarb, 175
Rasch, 267
rat model, 138, 148
real world evidence, 368, 369
real-world, 359
recruitment assistance, 265
REDCap, 354
redox, 274
REFALS, 280
referral, 353
regional homogeneity, 249
register study, 381
register, 178
register-based, 183
registries, 192
registry, 287, 290
regression, 296
rehabilitation, 341
relatives, 323, 373
reldesemtiv, 266, 279
repeat expansion, 110
rescue, 133
research consortium, 264
research documentation, 354
respiratory biomarkers, 325
respiratory disturbance index, 327
respiratory failure, 347
respiratory function, 325, 328
respiratory insufficiency, 186
respiratory QoL, 371
resting-state fMRI, 261
retigabine, 238
retrotransposon capture sequencing, 94
review, 302
riluzole, 273, 365
R-loops, 170
RNA aptamer, 233
RNA binding protein, 118
RNA metabolism, 115
RNA, 209
RNA-binding proteins, 174
RNA-seq, 96
RNM, 262
robotic assistance systems, 366
round-robin, 211
ryanodine receptor, 155
saliva assessment, 345
salivation, 342
Sarm1, 135
saturated fatty acids, 146
SBMA, 276
secretions, 337
selective vulnerability, 144
self efficacy, 372
sensory circuit, 144
serological factors, 210
serum biomarker, 286
serum creatinine, 210
service delivery, 356
SG, 157
short form, 308
sialorrhoea, 238, 345
Sigma 1 receptor, 151
skeletal muscle mass, 210
sleep quality, 382
sleep study, 327
slow progression, 196, 288
slow vital capacity, 266, 278, 326
SMA, 114, 133, 206, 261
SMN, 114
smoking, 183, 184
SNPs, 102
social factors, 316
socio-economic inequalities, 365
SOD1 aggregate elimination, 217
SOD1 gene, 100
sod1 screen, 150
SOD1, 102, 105, 108, 109, 120, 121, 123, 147, 160, 168, 186, 213, 220, 223, 256
SOD1-G93A mouse model, 120, 143, 218, 225, 234
SOD1G93A, 142, 222, 228
sod1G93R zebrafish, 150
somatic mutation, 94
source analysis, 247
spasms, 278
spasticity, 376
speech and pause measures, 377
spinal cord MRI, 261
spinal cord reflexes, 244
spinal cord, 207
spinal onset, 284
splicing factors, 126
splicing mutation, 105
spontaneous low frequency oscillations, 249
spouse, 374
spreading, 290
SQSTM1/p62, 172
staging system, 210
staging, 253
standards of care, 369
stem cell derived neural replacement, 130
stem cells, 145, 276
stratification, 298
strength, 244, 355
stress granules, 151, 158, 170
stress, 197, 349
SUIT, 257
support, 350, 373
supportive care, 365
survey, 195
survival, 186, 187, 198, 274, 296, 326, 331, 334, 339, 345
swallowing, 330, 340, 342
symptom management, 344
symptom relief, 233
symptomatic and palliative pharmacotherapy, 375
synapse loss, 176
synaptotagmin 13, 232
synergy, 232
systematic review, 264, 380
target validation, 239
target, 239
tau pathogenesis, 148
TBK1, 113, 139, 153
TBSS, 257
TDP-43 pathology, 134, 151
TDP-43, 123, 124, 125, 126, 127, 128, 135, 136, 151, 158, 170, 172, 176, 230, 233, 255, 292, 300
technology, 366
telehealth, 355
telemedicine, 355
telemonitoring, 332
terminal stage, 384
tetrahydrocannabinol/cannabidiol, 376
TGFß signalin, 237
TGFbeta, 112
therapeutic strategies, 218
therapeutic target, 150
therapeutic, 219, 228, 235
therapy, 147
thoracic muslce, 247
thrombotic events, 169
time-sensitive communication, 378
timolol, 238
tongue, 342
TONiC study, 193, 194, 267, 311, 316, 317
TONiC, 194, 365
toxic glial activation, 235
TPPV, 338
tracheostomy invasive ventilation, 339, 383
tracheostomy, 330
training, 306
transcranial magnetic stimulation, 277
transcriptome, 97, 162
transcriptomics, 144
transmission, 145, 223
traumatic brain injury, 148
treatment adherence, 336
treatment satisfaction, 360
treatment, 238, 274, 358
trial, 274
TrkB receptors, 120
trophic factor, 222
troponin activator, 278, 279
troponin, 214
TUBA4A mutations, 103
tumour necrosis factor alpha, 131
Tunisia, 288
ubiquitin-proteasome system, 123
ultrasound, 262
UNC13A, 102
understanding, 319
upper motor neuron biomarkers, 250
upper motor neurons, 224, 284
uric acid, 364
validated antibodies, 173
validation, 308
VAPB, 138, 262
variant prioritisation, 91
variant, 108
VBM, 257
VCP, 167
virus infection and mouse model, 134
vital staining, 248
VITALITY-ALS, 266, 278
voice banking, 380
walkable period, 285
weight loss, 254, 345
WGS, 91
wheelchair, 366
WHODAS-2.0, 193
whole exome sequencing, 176
work, 323
youth caregiver, 372
zebrafish, 149, 224